Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$240000.0.

  • CytomX Therapeutics' Change in Receivables fell 14159.45% to -$240000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 28467.31%. This contributed to the annual value of -$329000.0 for FY2024, which is 9898.94% up from last year.
  • As of Q3 2025, CytomX Therapeutics' Change in Receivables stood at -$240000.0, which was down 14159.45% from -$87000.0 recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Change in Receivables registered a high of $34.2 million during Q4 2022, and its lowest value of -$34.9 million during Q1 2023.
  • Over the past 5 years, CytomX Therapeutics' median Change in Receivables value was $58000.0 (recorded in 2022), while the average stood at $43736.8.
  • Its Change in Receivables has fluctuated over the past 5 years, first surged by 3536804.12% in 2022, then crashed by 1514137.93% in 2023.
  • Quarter analysis of 5 years shows CytomX Therapeutics' Change in Receivables stood at -$97000.0 in 2021, then surged by 35368.04% to $34.2 million in 2022, then tumbled by 97.04% to $1.0 million in 2023, then crashed by 124.58% to -$249000.0 in 2024, then rose by 3.61% to -$240000.0 in 2025.
  • Its Change in Receivables stands at -$240000.0 for Q3 2025, versus -$87000.0 for Q2 2025 and -$1.1 million for Q1 2025.